Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization 论文

2019Toxicological Sciences引用 242
DOI
Computational Drug Discovery MethodsAnimal testing and alternativesBiosimilars and Bioanalytical Methods
Computational Drug Discovery MethodsAnimal testing and alternativesBiosimilars and Bioanalytical Methods
相关技术:Computational Drug Discovery MethodsBiosimilars and Bioanalytical Methods
关系图谱

Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization · 作者

R

Russell S. Thomas

T

Tara S. Barton‐Maclaren

M

M.M.M. Rasenberg

M

Maurice Whelan

J

Jason C. Lambert

M

Maureen R. Gwinn

T

Tina Bahadori

K

Kathleen C. Raffaele

S

Stiven Foster

J

J.L.C.M. Dorne

M

Michelle Angrish

J

Jia-Ying Joey Lee

A

Andrea Gissi

R

Ryan Lougee

J

Jill A. Franzosa

T

Tomasz Sobański

T

Tatiana I. Netzeva

P

P.G. Karamertzanis

L

Lit‐Hsin Loo

M

Matthew Gagné

K

Katie Paul Friedman